Target

IL-6

14 abstracts

Abstract
A potential best-in-class BCMA-CD19 bispecific CART with advanced safety by self-inhibiting IFNG signaling during CRS.
Org: Celledit, The Third Affiliated Hospital of Southern Medical University, The First Affiliated Hospital of University of Science and Technology of China, The Second Xiangya Hospital of Central South University,
Abstract
Association between circulating cytokines expression patterns and outcomes to immune-checkpoint (ICI)–based regimens in metastatic renal cell carcinoma (mRCC).
Org: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD,
Abstract
Phase I trial of chimeric anti-GPC3 scFv-CD3ε engineered T cells (CT0180) in patients with advanced hepatocellular carcinoma.
Org: CARsgen Therapeutics Ltd., Co., Shanghai, China, CARsgen Therapeutics, CARsgen Therapeutics, Inc, Houston, TX,
Abstract
Evaluation of prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) to inform the management of patients (pts) treated with teclistamab in MajesTEC-1.
Org: Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Vrije Universiteit Amsterdam, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania,
Abstract
Association between cervical immune markers and cervical high-risk HPV infections.
Org: University of Maryland School of Medicine, Institute of Human Virology Nigeria,
Abstract
Targeting regeneration capacity of stem cells to improve surgical wound healing outcomes in ovarian cancer patients.
Org: MD Anderson Cancer Center at Cooper, Rowan University School of Medicine, Cooper University Hospital,
Abstract
Immunological signature of patients with thymic epithelial tumors and Good syndrome: Correlation with clinical outcome.
Org: Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy, Rare Tumors Coordinating Center of Campania Region (CRCTR), Naples, Italy, Department of Translational Medical Sciences, University Federico II, Naples, Italy, Azienda Ospdaliera Universitaria Federico II, Naples, Italy,
Abstract
The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Pooled analysis of cytokine release syndrome across cohorts in patients with advanced synovial sarcoma.
Org: Memorial Sloan Kettering Cancer Center, Stanford Cancer Center, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Princess Margaret Cancer Centre,
Abstract
Cytology-histology correlation, time to diagnosis and time to therapy when cytology is performed in addition to biopsies in malignant spinal lesions of previously unknown malignant disease.
Org: Department of Oncology, Haematology and Bone Marrow Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Department of Orthopedics and Trauma Surgery, Section for Spine Surgery, University Hospital Hamburg Eppendorf, Hamburg, Germany, Institute of Pathology, University Hospital Hamburg Eppendorf, Hamburg, Germany, RKH Orthopädische Klinik Markgröningen gGmbH, Markgröningen, Germany, Department of Orthopedics and Trauma Surgery, University Hospital Hamburg Eppendorf, Hamburg, Germany,
Abstract
Serum IL-6 levels following siltuximab administration in Castleman disease.
Org: Perelman School of Medicine at the University of Pennsylvania, University of Pennsylvania, University of Arkansas for Medical Sciences (UAMS), Department of Medicine, Icahn School of Medicine at Mount Sinai, Perelman School of Medicine,
Abstract
Diagnostic and prognostic biomarker value of blood circulating inflammatory cytokines in hepatocellular carcinoma.
Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Texas MD Anderson Cancer Center,